5 completed, 3 recruiting, 2 not yet recruiting. 10 Phase 3.
By phase and status
Follow BI 456906: new trials by email Literature Review of BI 456906 trials Research Report on BI 456906
Trials (filtered) newest first · largest first
All 10 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Survodutide - Obesity Phase 3 Not yet recruiting 350 2026-11-07 2026-10-27 SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight Survodutide, Placebo - Obesity Phase 3 Not yet recruiting 600 2026-10-31 2026-10-30 A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar Placebo, Survodutide - Type 2 Diabetes Phase 3 Recruiting 600 2026-08-24 2026-10-29 LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis Survodutide, Placebo matching survodutide - Metabolic Dysfunction Associated Steatohepatitis Phase 3 Recruiting 1590 2024-11-12 2026-10-28 LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis Survodutide, Placebo - Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis Phase 3 Recruiting 1800 2024-10-14 2026-10-28 A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight survodutide, Placebo matching BI 456906 - Obesity, Overweight Phase 3 Completed 307 2024-02-06 2026-04-30 A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease Survodutide, Placebo matching survodutide - Obesity Phase 3 Completed 274 2024-01-16 2026-04-30 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight Survodutide, Placebo - Obesity, Diabetes Mellitus, Type 2 Phase 3 Completed 755 2023-11-27 2026-08-06 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight survodutide, Placebo - Obesity Phase 3 Completed 726 2023-11-25 2026-03-12 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) survodutide, Placebo - Obesity Phase 3 Completed 5530 2023-11-20 2026-10-29
Conditions studied Obesity (7) · Diabetes Mellitus, Type 2 (2) · Liver Cirrhosis (1) · Overweight (1)
Sponsors Boehringer Ingelheim (10)
Countries United States (8) · Australia (6) · Canada (6) · China (6) · Japan (6) · New Zealand (6) · United Kingdom (6) · Belgium (5) · Germany (5) · Netherlands (5) · Poland (5) · South Korea (5) · Czechia (4) · Hungary (4) · India (4)
Results publications PMID 39453356 , PMID 41187967 , PMID 41216778 , PMID 42219222 , PMID 42253238 , PMID 42599381 , PMID 42820639